Treatment-resistant schizophrenia: What role for mood stabilizers?
One-half of all seriously and persistently ill patients with schizophrenia may receive add-on lithium or anticonvulsants. Does the evidence support this strategy?
Disclosure
Dr. Citrome receives research grants/contracts from Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Co., Eli Lilly & Co., Janssen Pharmaceutica, and Pfizer Inc. He is a consultant to and/or speaker for Bristol-Myers Squibb Co., Eli Lilly & Co., Pfizer Inc., Abbott Laboratories, AstraZeneca Pharmaceuticals, and Novartis Pharmaceuticals Corp.
Acknowledgment
Adapted from Citrome L. “Antipsychotic polypharmacy versus augmentation with anticonvulsants: the U.S. perspective” (presentation). Paris: Collegium Internationale Neuro-Psychopharmacologicum (CINP), June 2004 [abstract in Int J Neuropsychopharmacol. 2004; 7(suppl 1):S69], and from Citrome L. “Mood-stabilizer use in schizophrenia: 1994-2002” (NR350) (poster). New York: American Psychiatric Association annual meeting, May 2004.
